A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

NCT03956550 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

259

Enrollment

INDUSTRY

Sponsor class

Stopped Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee

Conditions

Osteoarthritis of the Knee
Pain

Interventions

DRUG: REGN5069
DRUG: Matching Placebo

Sponsor

Regeneron Pharmaceuticals